- Delivering Pan India
Tofajak® (Tofacitinib) Tofacitinib 5 mg tablets by Cipla. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Tofacitinib 5 mg |
|---|---|
| Manufacturer | Cipla |
| Country | India |
| Pack size | Tofacitinib 5 mg: 60 tablets (as shown on the carton) |
| Storage | Store as per the carton and strip; the US reference label describes 20°C to 25°C, protected from light. |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Tofajak® (Tofacitinib) Tofacitinib 5 mg Tablets — Oral Janus Kinase (JAK) Inhibitor Tablets: A Sourcing Guide for Hospitals and Pharmacies
Tofajak® is a brand of tofacitinib 5 mg film-coated tablets marketed in India by Cipla, shown on the carton as a pack of 60 tablets. According to the US prescribing information for the reference product Xeljanz, tofacitinib is a Janus kinase (JAK) inhibitor indicated for adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. Indications in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe tofacitinib, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Tofajak® (tofacitinib) Tofacitinib 5 mg tablets to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the immunosuppressant medicines category. Supply is in bulk/wholesale quantities only.
Tofajak contains tofacitinib 5 mg in film-coated tablets, supplied in the pack size listed below.
How it works, according to the label: The reference label describes tofacitinib as a Janus kinase (JAK) inhibitor; JAK enzymes are involved in the signalling of several cytokines that take part in immune and inflammatory processes.
The current US prescribing information for XELJANZ® (tofacitinib) tablets (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Tofajak pack insert.
The reference label summarises its Clinical Studies by indication. In rheumatoid arthritis, a placebo-controlled trial of tofacitinib monotherapy was published by Fleischmann et al. in the New England Journal of Medicine in 2012, and the post-authorisation ORAL Surveillance safety study (cardiovascular and cancer risk with tofacitinib) was published by Ytterberg et al. in the same journal in 2022. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Tofacitinib 5 mg | Film-coated tablets | 60 tablets (as shown on the carton) |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, rheumatology and gastroenterology department buyers and pharmacies that source immunomodulator products. Tofacitinib is prescribed and supervised by a physician, as described in the prescribing information.
The reference label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. It lists upper respiratory tract infection, nasopharyngitis, diarrhoea and headache among the most common adverse reactions in adults. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Tofajak carton and strip. For reference, the US Xeljanz label describes storage at 20°C to 25°C in the original container, protected from light. Keep out of reach of children.
Tofajak is marketed by Cipla. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Tofajak through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Tofajak available in India?
A.K. Pharma supplies Tofajak (tofacitinib) Tofacitinib 5 mg tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Tofajak contain?
Tofacitinib, a Janus kinase (JAK) inhibitor, in 5 mg film-coated tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Tofajak be stored?
Follow the carton and strip; the US reference label describes 20°C to 25°C, protected from light.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
